Open-Label, Phase Ii Study Of Ladiratuzumab Vedotin (Lv) For Advanced Gastric And Gastroesophageal Junction Adenocarcinoma (Sgnlva-005, Trial-In-Progress).

Amna Falak Sher,Justine Yang Bruce,Sung Yong Oh,Ian Churchill Anderson,Do-Youn Oh,Louise M. Nott, Jong-Seok Lee,Chia-Chi Lin,Ranee Mehra,Byoung Yong Shim,Wu-Chou Su,Troy H. Guthrie,Nashat Y. Gabrail,Rachel E. Sanborn,Arielle Shebay Lee, Diego Luigi Cortinovis,Paul Swiecicki,Yinghui Wang,Zejing Wang,Jae Yong Cho

JOURNAL OF CLINICAL ONCOLOGY（2021）

Cited 2|Views13

No score

Abstract

TPS256Background: LIV-1 is a transmembrane protein expressed in a variety of cancer types. SGN-LIV1A, or ladiratuzumab vedotin (LV), is a novel investigational humanized IgG1 antibody-drug conjugat...

Translated text

Key words

Breast Cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined